Wellington Management Group LLP Grows Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Wellington Management Group LLP increased its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 18.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 28,461,994 shares of the biopharmaceutical company's stock after acquiring an additional 4,497,950 shares during the quarter. Wellington Management Group LLP owned about 9.26% of Amicus Therapeutics worth $268,112,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. denkapparat Operations GmbH acquired a new stake in shares of Amicus Therapeutics during the fourth quarter worth about $171,000. Norges Bank bought a new position in shares of Amicus Therapeutics during the fourth quarter worth about $29,033,000. Prudential Financial Inc. raised its position in Amicus Therapeutics by 4.6% in the 4th quarter. Prudential Financial Inc. now owns 479,449 shares of the biopharmaceutical company's stock valued at $4,516,000 after buying an additional 21,000 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Amicus Therapeutics by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 29,258,963 shares of the biopharmaceutical company's stock valued at $275,619,000 after purchasing an additional 458,143 shares during the last quarter. Finally, Fox Run Management L.L.C. lifted its position in Amicus Therapeutics by 93.1% during the 4th quarter. Fox Run Management L.L.C. now owns 62,570 shares of the biopharmaceutical company's stock worth $589,000 after buying an additional 30,162 shares in the last quarter.

Amicus Therapeutics Trading Down 6.3 %

Amicus Therapeutics stock traded down $0.50 during mid-day trading on Friday, hitting $7.50. 3,184,754 shares of the stock were exchanged, compared to its average volume of 2,537,963. The firm's fifty day simple moving average is $9.16 and its two-hundred day simple moving average is $9.88. The company has a quick ratio of 2.42, a current ratio of 3.39 and a debt-to-equity ratio of 2.01. Amicus Therapeutics, Inc. has a 12 month low of $7.39 and a 12 month high of $12.65. The stock has a market capitalization of $2.30 billion, a price-to-earnings ratio of -41.67, a PEG ratio of 1.51 and a beta of 0.69.

Remove Ads

Analyst Upgrades and Downgrades

FOLD has been the subject of several recent analyst reports. StockNews.com downgraded Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Thursday, February 20th. Wells Fargo & Company dropped their price target on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research note on Thursday, February 20th. Needham & Company LLC reaffirmed a "hold" rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Cantor Fitzgerald restated an "overweight" rating and set a $21.00 price objective on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. Finally, Morgan Stanley reissued an "equal weight" rating and set a $12.00 target price (down previously from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $16.75.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.